Sarah Cannon Research Institute at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Sarah Cannon Research Institute takes part in 6 sessions at ESMO 2026 in Madrid. Its program centres on early drug development, from new ways to reach hard-to-drug targets to next-generation therapies for metastatic breast cancer and an oral androgen receptor-targeted drug in prostate cancer. Other sessions cover metastatic uveal melanoma, patritumab deruxtecan in melanoma and follow-up testing after multi-cancer early detection.

Organization

ESMO 2026 Attendance

Sarah Cannon Research Institute

Nashville, TN

sarahcannon.com

CRO & services

Oncology research organization based in Nashville, Tennessee, running cancer clinical trials across a network of US community sites.

Satellite

Fri Oct 23
18:45–19:00

Persistent Unmet Need in mUM: Limitations of Current Approaches

Servier - Toward a New Paradigm in Metastatic Uveal Melanoma: From Biological Insight to Practical Treatment Strategies

Melanoma & skin cancers

Abstract

Sat Oct 24
10:25–10:35

2216O - Safety and efficacy of JNJ-6143, a first-in-class oral AR-targeted regulated induced proximity targeting chimera at the optimal dose for further development in patients with mCRPC/mAPMR, including high-risk molecular features

Proffered paper: Genitourinary tumours, prostate, penile and testils

Genitourinary cancers

Talk

Sat Oct 24
14:45–15:05

Drugging the undruggables: The next wave of targeted therapies

YO Lecture: What to expect from precision medicine in the next decade

Biomarkers & precision oncology

Talk

Sat Oct 24
16:45–17:00

Next generation therapies

Novel concepts for metastatic breast cancer: Looking to the future

Breast cancerBiomarkers & precision oncology

Abstract

Sun Oct 25
10:15–10:20

2073RO - Patritumab Deruxtecan (HER3-DXd) in Melanoma After Anti-PD-(L)1 Therapy: Primary Analysis From HERTHENA-PanTumor01

Rapid oral: Melanoma and other skin tumours

Melanoma & skin cancers

Abstract

Mon Oct 26
15:22–15:27

1151RO - Efficiency and Safety of Cancer Signal Origin (CSO)-Guided Diagnostic Workups Following Multi-Cancer Early Detection (MCED) Testing: Results from PATHFINDER 2 (PF2)

Rapid oral: Prevention, early detection and intervention

Instantly find 20 buyers from Sarah Cannon Research Institute

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction